Page 1

Ao en los ASX 27 October 2021 Announcement 2021 Annual General Meeting Presentation Cogstate Cogstate Limited ABN 80 090 975 723 Suite 117 425 Smith Street Fitzroy Victoria 3065 Australia P +61 3 9664 1300 F +61 3 9664 1301 W cogstate.com Cogstate ( ASX.CGS ) attaches its 2021 Annual General Meeting Presentation , being provided to shareholders at today's meeting . For further information contact : Brad O'Connor , Chief Executive Officer , boconnor@cogstate.com This announcement was authorised for release by a sub - committee of the Board of Directors of Cogstate Ltd. About Cogstate Cogstate Ltd ( ASX : CGS ) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare . Cogstate technologies provide rapid , reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment ( eCOA ) solutions to replace costly and error prone paper assessments with real - time data capture . The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches , advanced analytics and scientific consulting . For over 20 years , Cogstate has proudly supported the leading - edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world . In the Healthcare market , in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical company Eisai , under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets . In October 2020 , Cogstate extended its agreement with Eisai to the Rest of the World . The product , branded as NouKNOW , launched in Japan on 31 March 2020 ( nouknow.jp ) . For more information , please visit www.cogstate.com .